These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37388769)

  • 21. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors.
    Huo Y; Zhang H; Sa L; Zheng W; He Y; Lyu H; Sun M; Zhang L; Shan L; Yang A; Wang T
    J Transl Med; 2023 Mar; 21(1):225. PubMed ID: 36978075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
    Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
    Front Immunol; 2022; 13():867154. PubMed ID: 35603195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human chimeric antigen receptor macrophages for cancer immunotherapy.
    Klichinsky M; Ruella M; Shestova O; Lu XM; Best A; Zeeman M; Schmierer M; Gabrusiewicz K; Anderson NR; Petty NE; Cummins KD; Shen F; Shan X; Veliz K; Blouch K; Yashiro-Ohtani Y; Kenderian SS; Kim MY; O'Connor RS; Wallace SR; Kozlowski MS; Marchione DM; Shestov M; Garcia BA; June CH; Gill S
    Nat Biotechnol; 2020 Aug; 38(8):947-953. PubMed ID: 32361713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
    Antoñana-Vildosola A; Zanetti SR; Palazon A
    Int Rev Cell Mol Biol; 2022; 370():123-147. PubMed ID: 35798503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
    Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
    Front Immunol; 2021; 12():782775. PubMed ID: 34790207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
    Yu T; Yu SK; Xiang Y; Lu KH; Sun M
    Front Immunol; 2022; 13():936496. PubMed ID: 35903099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
    Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
    Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting macrophages: a novel treatment strategy in solid tumors.
    Liu M; Liu L; Song Y; Li W; Xu L
    J Transl Med; 2022 Dec; 20(1):586. PubMed ID: 36510315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.
    Shin S; Lee P; Han J; Kim SN; Lim J; Park DH; Paik T; Min J; Park CG; Park W
    Tissue Eng Regen Med; 2023 Jun; 20(3):371-387. PubMed ID: 36867402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging advances in engineered macrophages for tumor immunotherapy.
    Hu J; Yang Q; Yue Z; Liao B; Cheng H; Li W; Zhang H; Wang S; Tian Q
    Cytotherapy; 2023 Mar; 25(3):235-244. PubMed ID: 36008206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bright future or blind alley? CAR-T cell therapy for solid tumors.
    Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
    Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
    Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy.
    Kang M; Lee SH; Kwon M; Byun J; Kim D; Kim C; Koo S; Kwon SP; Moon S; Jung M; Hong J; Go S; Song SY; Choi JH; Hyeon T; Oh YK; Park HH; Kim BS
    Adv Mater; 2021 Oct; 33(43):e2103258. PubMed ID: 34510559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.